$30.90
1.505.1%
Last update: Nov 5, 9:28 AM

Amylyx Pharmaceuticals (AMLX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.37 | $-0.35 | $-0.34 | $-0.33 |
| Actual | $-0.38 | $-0.39 | $-0.37 | $-0.30 |
| Surprise | -2.70% | -11.4% | -8.82% | +9.09% |
| Revenue | ||||
| Estimate | $41600 | — | — | — |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | -100.0% | — | — | — |
| Metric | Q4 '26E |
|---|---|
| Earnings Per Share (Non-GAAP) | |
| Consensus | $-0.37 |
| Revenue | |
| Consensus | $-41600 |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.38 | $-0.37 | -2.70 % |
| Q2 | Aug 6, 2026 | $-0.39 | $-0.35 | -11.4 % |
| Q1 | May 7, 2026 | $-0.37 | $-0.34 | -8.82 % |
| Q4 | Mar 3, 2026 | $-0.30 | $-0.33 | 9.09 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $0 | $41.60K | -100.0 % |
| Q2 | Aug 8, 2024 | $-1.20M | $10.66M | -111.3 % |
| Q1 | May 9, 2024 | $88.64M | $98.35M | -9.87 % |
| Q4 | Feb 22, 2024 | $108.45M | $106.96M | 1.39 % |